317 related articles for article (PubMed ID: 36811807)
1. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment.
Yegya-Raman N; Berlin E; Feigenberg SJ; Ky B; Sun L
Curr Oncol Rep; 2023 May; 25(5):433-444. PubMed ID: 36811807
[TBL] [Abstract][Full Text] [Related]
2. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.
Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T
Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849
[TBL] [Abstract][Full Text] [Related]
3. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.
Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE
Therapie; 2022; 77(2):197-206. PubMed ID: 34895759
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
5. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
6. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
7. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
Achim A; Liblik K; Gevaert S
Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Toxicities in Pediatric Cancer Survivors.
Ryan TD; Nagarajan R; Godown J
Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
[TBL] [Abstract][Full Text] [Related]
10. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
[TBL] [Abstract][Full Text] [Related]
11. Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives.
Cautela J; Lalevée N; Ammar C; Ederhy S; Peyrol M; Debourdeau P; Serin D; Le Dolley Y; Michel N; Orabona M; Barraud J; Laine M; Bonello L; Paganelli F; Barlési F; Thuny F
Int J Cardiol; 2016 Dec; 224():366-375. PubMed ID: 27673693
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1.
Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
Expert Opin Drug Saf; 2018 Sep; 17(9):875-892. PubMed ID: 30126304
[TBL] [Abstract][Full Text] [Related]
13. Cardio-oncology: management of cardiovascular toxicity.
Markman TM; Markman M
F1000Res; 2019; 8():. PubMed ID: 30755794
[TBL] [Abstract][Full Text] [Related]
14. Use of new and emerging cancer drugs: what the cardiologist needs to know.
Fabiani I; Chianca M; Aimo A; Emdin M; Dent S; Fedele A; Cipolla CM; Cardinale DM
Eur Heart J; 2024 Jun; 45(22):1971-1987. PubMed ID: 38591670
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
16. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment.
Lenneman CG; Sawyer DB
Circ Res; 2016 Mar; 118(6):1008-20. PubMed ID: 26987914
[TBL] [Abstract][Full Text] [Related]
17. Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship.
de Wall C; Bauersachs J; Berliner D
Clin Exp Metastasis; 2021 Aug; 38(4):361-371. PubMed ID: 34117981
[TBL] [Abstract][Full Text] [Related]
18. The Role of Cardiovascular Magnetic Resonance for Surveillance of Cardiac Performance upon Receipt of Potentially Cardiotoxic Cancer Therapeutics.
Parashar A; Hundley WG
Curr Cardiol Rep; 2018 Oct; 20(12):142. PubMed ID: 30367282
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease in adult survivors of childhood cancer.
Lipshultz SE; Franco VI; Miller TL; Colan SD; Sallan SE
Annu Rev Med; 2015; 66():161-76. PubMed ID: 25587648
[TBL] [Abstract][Full Text] [Related]
20. Multimodality Imaging for Cardiotoxicity: State of the Art and Future Perspectives.
Artico J; Abiodun A; Shiwani H; Kurdi H; Chen D; Tyebally S; Moon JC; Westwood M; Manisty CH
J Cardiovasc Pharmacol; 2022 Oct; 80(4):547-561. PubMed ID: 35522143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]